Skip to Content

Press Releases

Date Title and Summary Additional Formats
Toggle Summary Fluidigm Announces Second Quarter 2019 Financial Results
Second Quarter Revenue Increased 7 Percent to $28.2 Million Mass Cytometry Revenue Growth of 28 Percent in Second Quarter Expansion of Mass Cytometry Products with New Metal Markers and Imaging Mass Cytometry Panel Kits, Advanced CyTOF Software Introduction of Nanoscale Automated RNA-Seq NGS
View HTML
Toggle Summary Jonathan Day Named VP, Commercial Operations, Americas
Seasoned Commercial Leader with Track Record in Life Sciences and Diagnostics SOUTH SAN FRANCISCO, Calif. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of Jonathan Day as Vice President, Commercial Operations, Americas .
View HTML
Toggle Summary Fluidigm to Automate RNA Sequencing Library Preparation Using Microfluidics Technology
Automated Nanoscale RNA Library Preparation for Next-Generation Sequencing to Deliver Significant Savings and Workflow Efficiency for the Molecular Laboratory SOUTH SAN FRANCISCO, Calif. , Aug. 01, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools
View HTML
Toggle Summary Fluidigm Announces 3rd Annual Imaging Mass Cytometry User Group Meeting
Fluidigm Invites Researchers to the Largest Global Imaging Mass Cytometry Conference in Zurich, Switzerland SOUTH SAN FRANCISCO, Calif. , July 30, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through
View HTML
Toggle Summary Bill W. Colston Named to Fluidigm Board of Directors
Senior Biotechnology Leader with Broad Expertise in Life Science and Digital Health SOUTH SAN FRANCISCO, Calif. , July 25, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced the appointment of Bill W. Colston to the company’s Board of Directors.
View HTML
Toggle Summary Fluidigm Announces Conference Call and Webcast of Second Quarter 2019 Financial Results
SOUTH SAN FRANCISCO, Calif. , July 03, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive health insight, announced today that it will report second quarter 2019 financial results on Thursday,
View HTML
Toggle Summary Fluidigm Highlights New Advancements in Deep Cellular Profiling from Circulation to Tissue at CYTO 2019
Leading translational and clinical researchers will showcase how Fluidigm products are revolutionizing highly multiplexed cell and tissue characterization, biomarker discovery and therapeutic research development in more than 70 presentations and posters SOUTH SAN FRANCISCO, Calif.
View HTML
Toggle Summary Fluidigm Introduces Three Imaging Mass Cytometry Panel Kits and Advanced CyTOF Software to Accelerate Immuno-Oncology Research
Illuminating the diversity of immune cell phenotypes and function in the context of the tumor microenvironment, all in a single scan SOUTH SAN FRANCISCO, Calif. , June 19, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to
View HTML
Toggle Summary Fluidigm Scales Highly Multiplexed Cell Analysis with Introduction of Seven New Metal Markers
Powering industry-leading CyTOF technology to deliver new insights in translational and clinical research SOUTH SAN FRANCISCO, Calif. , June 17, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM), an innovative biotechnology tools provider with a vision to improve life through
View HTML
Toggle Summary Oncology Researcher Andrew Quong Joins Fluidigm as Chief Science Officer
SOUTH SAN FRANCISCO, Calif. , June 04, 2019 (GLOBE NEWSWIRE) -- Fluidigm Corporation (NASDAQ:FLDM) today announced that Andrew Quong , PhD, has joined the company as its first-ever Chief Science Officer.  Quong will lead the company’s strategy for the generation of bold scientific insights in
View HTML